Prostate cancer: Radiopharmaceuticals. Part 2 - PSMA theranostics

December 06, 2023 00:21:48
Prostate cancer: Radiopharmaceuticals. Part 2 - PSMA theranostics
COR2ED - Oncology Medical Conversation
Prostate cancer: Radiopharmaceuticals. Part 2 - PSMA theranostics

Dec 06 2023 | 00:21:48

/

Show Notes

Dr. Tanya Dorff (City of Hope Comprehensive Cancer Center, Los Angeles, USA) and Dr. Phillip Koo (Banner MD Anderson Cancer Center, Arizona, USA) discuss the latest developments in the field of radiopharmaceuticals and their use in Prostate Cancer.

This second episode focuses on PSMA-targeted radiopharmaceuticals and how PSMA can be a target for imaging as well as for therapies. Efficacy and safety data from the phase 2 TheraP study are discussed which investigated lutetium-PSMA versus cabazitaxel in patients with mCRPC who had progressed on docetaxel. The experts also discuss the ongoing VISION trial and what the results may mean for clinical practice as well as other ongoing trials looking at lutetium-PSMA in combination with other prostate cancer therapies such as PARP inhibitors, immunotherapies, hormonal therapies and chemotherapy. Treatment sequencing is also considered in terms of where lutetium-PSMA fits into clinical practice for mCRPC patients and how the treatment compares to Radium-223.

Other Episodes

Episode

January 10, 2024 00:31:12
Episode Cover

Treatment optimization in mCRC: third-line and beyond

Treatment of advanced colorectal cancer should be considered a continuum of care and patients should be offered as many life prolonging therapies as possible. ...

Listen

Episode

December 06, 2023 00:21:09
Episode Cover

Colorectal cancer: Treatment sequencing in advanced mCRC

This podcast episode discusses treatment sequencing in advanced metastatic colorectal cancer (mCRC) patients, third line and beyond.  Dr Shubham Pant from MD Anderson Cancer...

Listen

Episode

February 17, 2025 00:11:28
Episode Cover

Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions

Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions   Key clinical takeaways:   MMR status should be tested in all patients at diagnosis and...

Listen